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A B S T R A C T   
Background: Psychomotor Retardation is a key symptom of Major Depressive Disorder. According to the literature 
its presence may affect the prognosis of treatment. Aim of the present study is to investigate the prognostic role of 
Psychomotor Retardation in patients with unipolar Psychotic Depression who are under antidepressant 
treatment. 
Methods: The Salpetriere Retardation Rating Scale was administered at baseline and after 6 weeks to 122 patients 
with unipolar Psychotic Depression who were randomly allocated to treatment with imipramine, venlafaxine or 
venlafaxine plus quetiapine. We studied the effects of Psychomotor Retardation on both depression and psychosis 
related outcome measures. 
Results: 73% of the patients had Psychomotor Retardation at baseline against 35% after six weeks of treatment. 
The presence of Psychomotor Retardation predicted lower depression remission rates in addition to a higher 
persistence of delusions. After six weeks of treatment, venlafaxine was associated with higher levels of Psy-
chomotor Retardation compared to imipramine and venlafaxine plus quetiapine. 
Conclusions: Our data confirm that Psychomotor Retardation is a severity marker of unipolar Psychotic 
Depression. It is highly prevalent and predicts lower effectivity of antidepressant psychopharmacological 
treatment.   
1. Introduction 
Psychomotor Retardation is a key symptom of Major Depressive 
Disorder (MDD) (American Psychiatric Association, 2013). It is char-
acterized by slowness in both cognitive and motor processing and can be 
observed in speech, thinking and body movements (Schrijvers et al., 
2008). In patients with unipolar depression prevalences of 60–70% have 
been established (Novick et al., 2005). 
Psychomotor Retardation is a severity marker of depression. It is 
associated with several characteristics indicating a severe course of 
depression including an early age of onset, a longer duration of illness, a 
higher number of depressive episodes and increased rates of suicide 
attempts (Calugi et al., 2011). In addition, Psychomotor Retardation is 
the primary symptom delineating the more severe melancholic subtype 
from non-melancholic depression (Parker, 2000; Parker and McCraw, 
2017). 
Possibly related to its association with depression severity, literature 
suggests that the presence of Psychomotor Retardation could inform 
treatment choice: patients with Psychomotor Retardation responded 
poorly to Selective Serotonin Reuptake Inhibitors (SSRIs) (Schrijvers 
et al., 2008; Ulbricht et al., 2018). More positive results were found for 
Tricyclic Antidepressants (TCAs), other dual acting antidepressants and 
combinations of serotonergic and noradrenergic agents (Sobin and 
Sackeim, 1997; Schrijvers et al., 2008). Psychomotor Retardation pre-
dicted a higher treatment response in patients selected for Electrocon-
vulsive Therapy (Hickie et al., 1996; van Diermen et al., 2019; Heijnen 
et al., 2019). 
Although Psychomotor Retardation is very common in Psychotic 
Depression, with a reported prevalence of up to 75% (Parker et al., 
1991), little research has been conducted to its role in the 
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pharmacological treatment of patients with Psychotic Depression. 
Additional research is important to conclude if Psychomotor Retarda-
tion influences the outcome of pharmacological treatment, as is the case 
in non- Psychotic Depression. The main aim of this study is to evaluate 
the role of Psychomotor Retardation as a predictor of treatment 
response, taking different outcome measures into account. Based on the 
associations with severity in patients with non-psychotic MDD (Calugi 
et al., 2011), we hypothesize that the presence of Psychomotor Retar-
dation predicts a lower response to pharmacological treatment. 
2. Methods 
We used data from a multicentre, double-blind randomized 
controlled trial comparing the efficacy of imipramine (Tricyclic Anti-
depressant), venlafaxine (Serotonin-Noradrenaline Reuptake Inhibitor) 
and venlafaxine plus quetiapine (2nd generation antipsychotic agent) in 
patients with unipolar Psychotic Depression. The complete description 
of the study can be found elsewhere (Wijkstra et al., 2010). Here, we 
present a summary of the methods. 
2.1. Patients 
Hospitalized patients aged 18–65 years were included if they met 
DSM-IV-TR criteria (American Psychiatric Association, 2000) for uni-
polar major depressive episode with psychotic features and a score ≥18 
on the Hamilton Rating Scale for Depression (HAM-D; 17 item version; 
Hamilton, 1960) both at the screening visit and at the day prior to start 
of medication. Exclusion criteria were: an acute indication for electro-
convulsive therapy (ECT); mental retardation; alcohol or substance 
abuse or dependence within 3 months of enrolment; any serious somatic 
illness; somatic medication affecting mood; contraindications for study 
medication; adequate previous treatment of the current episode with 
imipramine (≥4 weeks with adequate plasma levels (200–300 μg/l)) or 
venlafaxine (≥4 weeks ≥ 300 mg ⁄ day). 
2.2. Study design 
The study was approved by the ethical review board of the University 
Medical Centre Utrecht, and by the local review boards of the partici-
pating centres, and performed according to the rules of Good Clinical 
Practice. All patients, or their legal relatives in case of incapacity, gave 
written informed consent prior to enrolment. 
The diagnosis of unipolar Psychotic Depression was confirmed using 
the Structured Clinical Interview for DSM-IV Axis I disorders (First, 
1999). Baseline assessments also included a psychiatric history, a 
medical history and a physical examination including vital signs and 
routine laboratory assessments. There were weekly assessments of 
depressive symptoms (HAM-D) and positive psychotic symptoms (hal-
lucinations and/or delusions). All assessments were performed by 
trained physicians. 
All patients were drug free for at least 4 days before the start of 
treatment After inclusion, they were randomized to 7 weeks double- 
blind treatment with imipramine, venlafaxine, or venlafaxine plus 
quetiapine, while stratifying for centre. Study drugs were dosed to reach 
an adequate plasma level (200–300 μg/l for imipramine) or the 
maximum dose (375 mg/day for venlafaxine and 600 mg/day for que-
tiapine). As concomitant psychotropic medication, only benzodiaze-
pines at a maximum of 3 mg lorazepam equivalent per day were 
allowed. 
2.3. Psychomotor retardation 
Psychomotor Retardation was measured at baseline and after 6 
weeks using the Salpetriere Retardation Rating Scale (SRRS; Dantchev 
and Widlocher, 1998). The SRRS is a clinician rated instrument, con-
sisting of 14 individual items plus a final appreciation. Items are scored 
on a five point likert scale ranging from 0 (normal) to 4 (severe distur-
bance) and refer to motor function, speech and objective and subjective 
mental activity (Dantchev and Widlocher, 1998). For the Dutch version 
good internal consistency was confirmed. Interrater reliability was suf-
ficient to good. Convergent validity was indicated by a high association 
between the SRRS score and the retardation items of the Comprehensive 
Psychopathological Rating Scale (de Weme et al., 1996). 
Measures of Psychomotor Retardation:  
a. The SRRS-6 score, is the sum score of the first six SRRS items. This 
subscale includes only objective (assessor observed) items, while the 
complete SRRS scale also relies on the subjective experiences of 
patients which might be biased by depression (Brebion et al., 1997; 
Lampe et al., 2001; Smith et al., 1994).  
b. Clinical Psychomotor Retardation, defined as a total SRRS score 
above the cut-off of 20 points (Widlocher, 1983).  
c. HAM-D retardation (HAM-D item 8; score 0 or 1 coded as absent; 
score ≥2 coded as present). This dichotomized score reflects pres-
ence or absence of psychomotor retardation, not severity. In the 
present study the HAM-D retardation score was only used for cross- 
validation of the SRRS based scores. 
2.4. Outcome measures 
Outcome of pharmacological treatment was measured after 7 weeks. 
The primary outcome measure is response, defined as a HAM-D score of 
≤14 and a ≥50% decrease from baseline. The maximum score of 14 in 
this definition was also applied in the primary study (Wijkstra et al., 
2010) and was chosen to preclude moderate to severe depression in 
patients who reached response. Secondary outcome measures were: a) 
treatment remission defined as HAM-D ≤7; b) the presence of halluci-
nations and c) the presence of delusions. Assessments of hallucinations 
and delusions were based on psychiatric interview and clinical obser-
vations (scored 1 if present and 0 if absent). 
Administration of HAM-D, SRRS and other measures was discussed 
at regular meetings with the researchers from all participating sites. 
Inter-rater reliability as indicated by the intraclass correlation coeffi-
cient and based on three patients and eight raters was 0.93 (95% CI: 
0.74; 1.00) for the HAM-D. 
2.5. Statistical analysis 
Univariate associations were expressed as Pearson’s correlation co-
efficients. For testing of changes in categorical and dimensional mea-
sures we used chi-square tests and paired t-tests respectively. 
Logistic regression analysis was carried out to study the prognostic 
effects of Psychomotor Retardation on the outcome of psychopharma-
cological treatment. Here we used the intention-to-treat (ITT) principle. 
According to this principle all randomized patients are included for 
statistical analysis regardless of whether they completed follow-up. In 
case of dropout we used the last observation carried forward method. 
The primary analyses were adjusted for the most important potential 
confounders: age, gender, baseline HAM-D score without retardation 
item, recent antipsychotic medication and drug type. Subsequently these 
analyses were adjusted for the number of previous depressive episodes 
and duration of the current episode. In supplementary analyses we 
investigated the contribution of the interactions of treatment strategy 
and Psychomotor Retardation by adding the three products of treatment 
group by baseline SRRS-6 score. 
Finally, in a multiple regression analysis we compared the effects of 
the treatment conditions on the outcome of psychomotor retardation 
(SRRS-6-score) adjusting for the baseline SRRS-6 score, baseline HAM-D 
score without retardation item age and gender. 
All analyses were conducted with SPSS 25.0 for Windows (SPSS IBM 
CORP, 2017). The significance level was set at p < 0.05 (two sided). 
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3. Results 
Table 1 presents the baseline characteristics of the study sample. A 
total of 122 patients was included After randomisation 39 patients 
(32.0%) were treated with venlafaxine, 42 (34.4%) with imipramine 
and 41 (33.6%).with venlafaxine plus quetiapine. Treatment groups 
were comparable for baseline clinical and demographic characteristics. 
Eight subjects used antipsychotic medication before the one-week 
washout period. The association between antipsychotic use and base-
line SRRS-6 score was insignificant (r = 0.006 NS). 
Correlations between the baseline measures of Psychomotor Retar-
dation were highly significant: SRRS-6 by SRRS total score r = 0.92 p <
0.001; SRRS-6 by HAM-D retardation item r = 0.77 p < 0.001. The 
SRRS-6 score had a positive significant association with the number of 
previous depressive episodes (r = 0.19 p = 0.03) and the baseline total 
HAM-D score (r = 0.28 p = 0.002). When the HAM-D retardation item 
was excluded from the total baseline HAM-D score, the association was 
no longer significant (r = 0.13 NS). Correlations between the SRRS-6 
score and other baseline clinical characteristics (duration current 
depressive episode, presence of delusions and hallucinations) and de-
mographic variables (age and gender) were low and insignificant. 
During treatment a total of 76.2% of the patients (n = 93) used 
benzodiazepines (imipramine group 32/42 (76.2%); venlafaxine group 
30/39 (76.9%); venlafaxine plus quetiapine group 31/41 (75.6%); Chi2 
= 0.02 NS). There were no significant associations between benzodi-
azepine use and SRRS-6 scores at baseline and after 6 weeks of treatment 
(baseline r = − 0.12 NS; after 6 weeks n = 103 r = − 0.13 NS). 
Table 2 presents the measures of Psychomotor Retardation at base-
line and after 6 weeks of treatment. Results are presented for categorical 
measures (Clinical Psychomotor Retardation defined as a SRRS score 
above 20; HAM-D retardation as an item score above 1) and for 
dimensional measures (SRRS total score and SRRS-6 score). In 73% of 
the patients there was evidence of Clinical Psychomotor Retardation at 
baseline which decreased to 35% after 6 weeks. Three patients who did 
not fulfil criteria at baseline developed Clinical Psychomotor Retarda-
tion during treatment. The decrease in retardation scores during treat-
ment was comparable for all Psychomotor Retardation measures (range 
31.1–40.2%). Taking only the results of patients with complete SRRS 
scores after six weeks into account, the change in SRRS-6 scores during 
treatment was significantly associated with the change in HAM-D scores 
(r = 0.28 p < 0.006 n = 103). After 6 weeks of treatment the correlation 
between the SRRS-6 score and the HAM-D score was 0.58 (p < 0.001 n 
= 103). 
Table 3 presents the HAM-D scores and the rates of positive psychotic 
symptoms at baseline and after 7 weeks of treatment. 
Hallucinations at baseline were present in a minority of the patients 
while almost all patients had delusions. In about half of the patients 
hallucinations had remitted after 7 weeks. Delusions remitted in about 
two thirds of the patients. 
Table 4 presents the associations between baseline Psychomotor 
Retardation (SRRS-6 score) and outcome measures after 7 weeks of 
treatment. Logistic regression analyses were adjusted for age, gender, 
baseline Hamilton score without retardation, antipsychotic medication 
before study start and treatment condition (imipramine, venlafaxine or 
venlafaxine plus quetiapine). Higher baseline SRRS-6 scores predicted 
significantly lower rates of HAM-D defined remission and higher 
persistence of delusions at follow up. The baseline SRRS-6 scores were 
not significantly associated with the other outcome measures (HAM-D 
defined response and hallucinations). Additional adjustment for 
depressive course characteristics (duration of the current episode and 
number of previous depressive episodes) did only slightly affect the 
results (for remission: B = − 0.082 (SE = 0.045) p = 0.066; for delusions: 
B = 0.118 (SE = 0.042) p = 0.005). 
Table 1 
Baseline demographic and clinical characteristics.   
Total group Venlafaxine Imipramine Venlafaxine plus Quetiapine Differences between treatment groupsa 
N = 122 N = 39 N = 42 N = 41 Statistics df p-value 
Age in years (M, SD) 51.0 (10.9) 50.0 (12.0) 51.9 (9.6) 50.9 (11.1) F = 0.3 2 0.73 
Female gender (N,%) 62 (50.8%) 17 (43.6%) 23 (54.8%) 22 (53.7%) χ2 = 1.2 2 0.55 
HAM-D (M,SD) 31.8 (5.1) 31.6 (4.6) 32.0 (5.3) 31.6 (5.4) F = 0.1 2 0.92 
SRRS (M, SD) 28.1 (10.4) 29.7 (10.9) 27.1 (10.3) 27.5 (10.1) F = 0.7 2 0.49 
Episode Duration in weeks (M,SD) 36.0 (86.8) 42.7 (110.9) 25.6 (32.2) 40.4 (98.8) F = 0.5 2 0.63 
Use of benzodiazepines (N,%)b 93 (76.2%) 30 (76.9%) 32 (76.2%) 31 (75.6%) χ2 = 0.0 2 0.99 
HAM-D: total score Hamilton Depression Rating Scale. 
SRRS: total score Salpetriere Retardation Rating Scale. 
M = Mean SD= Standard deviation. 
a Testing for differences between treatment groups One-way ANOVA for continuous variables; χ2-tests for dichotomous variables. 
b Numbers of patients using benzodiazepines during treatment. 
Table 2 
Measures of psychomotor retardation at baseline and after 6 weeks of treatment 
(n = 122).   
Baseline After 6 weeksa    
Categorical 
measures 





89 (73.0%) 43 (35.2%) 13.6 1 <0.001 
HAM-D 
retardation 
67 (54.9%) 29 (23.8%) 31.2 1 <0.001  
Dimensional 
measures 
Mean (SD) Mean (SD) t df p- 
value 
SRRS total score 28.1 10.4 16.8 (11.9) 11.4 121 <0.001 
SRRS-6 8.6 5.4 5.2 (4.9) 8.3 121 <0.001 
SRRS: Salpetriere Retardation Rating scale; HRI: HAM-D: Hamilton Rating Scale 
for Depression. 
a Last observation carried forward. 
Table 3 
Depressive symptoms, hallucinations and delusions at baseline and after 7 weeks 
of treatment (N = 122).   
Baseline Follow up  
(7 weeks) 
t df p-value 
HAM-D Mean (SD) 31.8 (5.1) 15.3 (10.6)a/b 17.2 121 <0.001   
Baseline Follow up  
(7 weeks) 
Chi2 df p-value 
Hallucinations N (%) 29 (23.8) 14 (11.5%)a 41.7 1 <0.001 
Delusions N (%) 111 (91.0) 37 (30.3%)a 5.3 1 <0.03 
HAM-D: Hamilton Rating Scale for Depression. 
a Last observation carried forward method. 
b Response n = 62 (50.8%); Remission n = 37 (30.3%). 
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In a subsequent analysis we added the interaction terms of Psycho-
motor Retardation (baseline SRRS-6 score) and the three treatment 
conditions. The results are presented in Table 5. There were no signifi-
cant effects for these retardation by treatment interactions on any of the 
outcome measures. 
Finally we studied the effects of treatment condition on the outcome 
of psychomotor retardation (SRRS-6 score) in a multiple regression 
analysis adjusting for baseline SRRS-6 score, baseline HAM-D score 
without retardation, age and gender. For these analyses we only 
included patients with complete SRRS-6 scores at follow up (n = 103). 
In the first analysis where imipramine was used as the reference, a 
significant positive effect was present for venlafaxine indicating higher 
retardation scores at follow up (B = 2.447 SE = 0.896 t = 2.73 p <
0.008). For treatment with venlafaxine plus quetiapine there was no 
significant effect compared to imipramine (B = 0.227 SE = 0.92 t =
0.254 p = 0.800). 
Repeating the analysis using venlafaxine plus quetiapine as the 
reference we found a significant effect in the same direction for patients 
who were treated with venlafaxine (B = 5.972 SE = 2.330 t = 2.563 p <
0.05). 
4. Discussion 
Psychomotor disturbance covers a group of clinical characteristics 
which can be observed and objectively measured (van Diermen et al., 
2018). It can be used for subtyping of disorders, and refers to the 
dysfunction of underlying neurobiologal pathways (Walther et al., 
2019). 
For unipolar depression Psychomotor Retardation has been identi-
fied as a severity marker which may also influence treatment choice. 
The present study investigates Psychomotor Retardation in a sample 
of well characterized patients with unipolar Psychotic Depression during 
the course of antidepressant pharmacological treatment. The main 
findings are:  
1. Clinical levels of Psychomotor Retardation were present in a large 
majority of the patients at baseline and remitted in more than 50% of 
the patients during treatment.  
2. Baseline Psychomotor Retardation predicted lower depression 
remission rates in addition to higher persistence of delusions.  
3. Patients using venlafaxine retained higher Psychomotor Retardation 
scores at follow-up compared to patients who were treated with 
imipramine or venlafaxine plus quetiapine. 
4.1. Prevalence and course of psychomotor retardation during treatment 
At baseline, 73% of the patients showed clinical levels of Psycho-
motor Retardation. This rate is in agreement with earlier studies. Parker 
et al. (1991) observed signs of retardation in about 75% of patients with 
Psychotic Depression compared to percentages below 50% in patients 
with endogenous depression and melancholic depression. In another 
sample, patients with Psychotic Depression presented higher rates of 
Psychomotor Retardation compared to patients with melancholic 
depression (Parker et al., 1997). Several other studies report high levels 
of Psychomotor Retardation in Psychotic Depression compared to 
non-psychotic depression (Coryell et al., 1984; Lattuada et al., 1999; 
Schatzberg and Rothschild, 1992). 
During treatment we observed a 30–40% reduction of Psychomotor 
Retardation according to both categorical and dimensional measures. 
This suggests that in a large proportion of the patients Psychomotor 
Retardation can be considered a state characteristic, which is in agree-
ment with the literature regarding non-psychotic depressed patients 
(Schrijvers et al., 2008). 
There was no age difference with respect to Psychomotor Retarda-
tion in our patients. Although, in general, elderly patients are at an 
increased risk for Psychomotor Retardation (Brodaty et al., 1997; 
Schrijvers et al., 2008), the absence of an observable association in our 
sample may be related to exclusion of patients over 65 years of age. The 
Table 4 
Effects of baseline psychomotor retardation (SRRS-6 score) on the four outcome measures. Results of logistic regression analysis.   
Hamilton- response Hamilton-remission 
Predictor Beta (SE) Wald df p-value Exp(B) Beta (SE) Wald df p-value Exp(B) 
SRRS-6 -,012 ,036 ,111 1 ,739 ,988 -,085 ,042 4,026 1 ,045 ,919   
Hallucinations after treatment Delusions after treatment 
Predictor Beta (SE) Wald df p-value Exp(B) Beta (SE) Wald df p-value Exp(B) 
SRRS-6 -,014 ,061 ,055 1 ,815 ,986 ,108 ,040 7,202 1 ,007 1,114 
All analyses based on last observation carried forward method. Analyses adjusted for age, gender, recent antipsychotic medication, baseline HAM-D score without 
retardation and treatment (imipramine, venlafaxine or venlafaxine plus quetiapine). 
SRRS: Salpetriere Retardation Rating Scale. 
Table 5 
Effects of drug - retardation interactions on the four outcome measures after 7 weeks of treatment. Results of logistic regression analysis.   
Hamilton- response Hamilton-remission 
Interaction term Beta (SE) Wald df p-value Exp(B) Beta (SE) Wald df p-value Exp(B) 
Imipramine *SRRS-6 ,023 ,085 ,071 1 ,790 1,023 ,054 ,101 ,284 1 ,594 1,055 
Venlafaxine *SRRS-6 ,014 ,097 ,020 1 ,888 1,014 ,114 ,105 1164 1 ,281 1,121   
Hallucinations after treatment Delusions after treatment 
Interaction term Beta (SE) Wald df p-value Exp(B) Beta (SE) Wald df p-value Exp(B) 
Imipramine*SRRS-6 ,032 ,160 ,040 1 ,841 1,033 ,111 ,104 1,132 1 ,287 1,117 
Venlafaxine*SRRS-6 ,000 ,157 ,000 1 ,999 1,000 ,047 ,108 ,192 1 ,661 1,048 
All analyses based on last observation carried forward method. Analyses adjusted for age, gender, recent antipsychotic medication, baseline HAM-D score without 
retardation, retardation (SRRS-6 score) and treatment (imipramine, venlafaxine). Venlafaxine plus quetiapine treatment and the interaction term of venlafaxine +
quetiapine*SRRS-6 served as reference variables. 
SRRS: Salpetriere Retardation Rating Scale. 
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observed lack of a gender difference in Psychomotor Retardation is in 
accordance to the literature (Schrijvers et al., 2008). 
4.2. Associations with baseline clinical variables 
Associations between Psychomotor Retardation and the number of 
previous depressive episodes are in agreement with the observations of 
Calugi et al. (2011) and Gorwood et al. (2014) in non-psychotic 
depressed patients, but have not been demonstrated in patients with 
Psychotic Depression before. As both severity and recurrence of 
depression are markers of familial occurrence (Janzing et al., 2009), 
Psychomotor Retardation may be an expression of genetic liability. In 
agreement, Parker (2000) reported that psychomotor disturbance, 
especially presenting at young age, is associated with a positive family 
history of depression. Alternatively, according to the scarring hypothesis 
of Gorwood et al. (2014), Psychomotor Retardation may be the conse-
quence of experiencing previous depressive episodes. To answer the 
question on the direction of association, prospective studies are 
necessary. 
4.3. Associations with treatment outcome 
Considering the outcome of treatment in Psychotic Depression, both 
depressive symptoms and psychotic symptoms should be taken into 
account. (Østergaard et al., 2014). The observation that higher baseline 
Psychomotor Retardation levels predict lower HAM-D remission rates is 
in accordance with studies in patients with non-psychotic depression 
(Calugi et al., 2011; Gorwood et al., 2014), but has not been reported 
before in patients with Psychotic Depression. As the attainment of 
remission decreases the risk for relapse, Psychomotor Retardation can be 
considered a negative predictor for the long term course of Psychotic 
Depression. Baseline levels of Psychomotor Retardation did not affect 
the HAM-D defined response rate. We can speculate about the reason 
why higher baseline retardation scores predicted lower rates of remis-
sion while no significant effect on response was found. The increasing 
association between Psychomotor Retardation and HAM-D symptoms 
during treatment (correlations rising from 0.28 (baseline) to 0.56 (6 
weeks)) suggests that depression symptoms unrelated to retardation are 
more responsive to treatment than retardation related symptoms. Given 
the low baseline correlation between retardation and depressive symp-
toms, we can assume that also in patients with higher baseline retar-
dation scores the majority of baseline depressive symptoms is unrelated 
to retardation (responsive to treatment). Therefore they can easily reach 
substantial symptom reductions (response). However especially in these 
patients substantial levels of the unresponsive retardation related 
depressive symptoms may persist, reducing their probability of reaching 
remission. 
In addition, higher baseline Psychomotor Retardation levels were 
associated with the persistence of delusions after treatment. Also this 
observation has not been reported before. It can be appreciated in the 
context of earlier observations taking different levels of explanation into 
account. At the neuropsychological level, the neurocognitive symptoms 
associated with Psychomotor Retardation including deficits in executive 
functions, speed of processing and verbal memory may interfere with 
reality testing (Guillem et al., 2008). At the biological level both psy-
chotic symptoms and Psychomotor Retardation may reflect disturbances 
in dopaminergic neurotransmission. For depression, neurobiological 
research suggests that Psychomotor Retardation is associated with ab-
normalities in connections between cortical and subcortical brain 
structures and altered dopaminergic neurotransmission (Buyukdura 
et al., 2011; Schrijvers et al., 2008). Finally at the syndromic level 
Psychomotor Retardation co-occurs with psychotic symptoms in several 
neuropsychiatric disorders including schizophrenia, delirium and Par-
kinson’s disease. Also for these disorders functional and or structural 
alterations in dopaminergic pathways play an important role in their 
pathophysiology. 
4.4. Associations with antidepressant pharmacotherapy 
In nonpsychotic unipolar depression, the presence of Psychomotor 
Retardation has been associated with a poor response to antidepressant 
pharmacotherapy, especially with respect to SSRI’s (Schrijvers et al., 
2008; Ulbricht et al., 2018)). We did not observe differences between 
treatment strategies (imipramine, venlafaxine or venlafaxine plus que-
tiapine) regarding the outcome of depression and positive psychotic 
symptoms. However, patients treated with venlafaxine had significantly 
higher scores of retardation at follow up compared to patients treated 
with imipramine or venlafaxine plus quetiapine. Interestingly, these 
findings partly parallel those of the primary study (Wijkstra et al., 2010) 
where venlafaxine plus quetiapine was also found superior to ven-
lafaxine alone with respect to treatment response. This result was un-
expected as according to the literature most of the dual acting 
antidepressants are thought to have beneficial effects on psychomotor 
retardation. It may be of clinical importance regarding the association of 
psychomotor retardation with treatment resistance in addition to 
several other characteristics indicating a more severe course of 
depression. 
Our study has a number of strengths: 
Patients were well characterized and constitute one of the largest 
samples with Psychotic Depression studied to date. A large number of 
potential confounders have been taken into account: 
a. Except study medication, participants were not allowed to use psy-
chotropic drugs apart from low doses of benzodiazepines.  
b. Patients with severe somatic or neurological disorders or substance 
use were excluded from participation thereby limiting the possibility 
that Psychomotor Retardation was a consequence of these disorders.  
c. Associations between Psychomotor Retardation and outcome were 
adjusted for clinical and demographic characteristics (age, gender 
and recent antipsychotic use) which may be associated with Psy-
chomotor Retardation levels. 
A limitation is that we used separate outcome variables for depres-
sive and psychotic symptoms whereas the recently developed Psychotic 
Depression Assessment Scale (PDAS) allows to take both symptom 
groups into account (Østergaard et al., 2014). 
5. Conclusion 
This study contributes to the literature by presenting several new 
findings regarding the role of Psychomotor Retardation in patients with 
unipolar Psychotic Depression. Combining its high prevalence and its 
predictive value for treatment outcome (lower remission rates and 
higher rates of delusions at follow up), we conclude that Psychomotor 
Retardation is a severity marker also in patients with Psychotic 
Depression. The results of this study can be generalized to other patients 
aged 18–65 years with a diagnosis of unipolar Psychotic Depression as 
our sample was recruited from a multi-centre study and the study was 
performed in the context of regular clinical patient care. 
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Dr. Birkenhäger reports grants from Lundbeck BV, unrelated to the 
submitted work;. 
Dr. Nolen reports grants from Astra Zeneca, grants from Wyeth, 
during the conduct of the study (see role of funding source). 
Acknowledgements 
The study team wishes to thank Jaap Wijksta for his leadership in this 
study; AstraZeneca and Wyeth for financial support and providing the 
study medication. 
References 
American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental 
Disorders: DSM-IV-TR. American Psychiatric Association, Washington D.C.  
American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental 
Disorders, fifth ed. American Psychiatric Publishing, Arlington, VA.  
Brebion, G., Smith, M.J., Widlocher, D., 1997. Discrimination and response bias in 
memory: effects of depression severity and psychomotor retardation. Psychiatr. Res. 
70 (2), 95–103. 
Brodaty, H., Luscombe, G., Parker, G., Wilhelm, K., Hickie, I., Austin, M.P., Mitchell, P., 
1997. Increased rate of psychosis and psychomotor change in depression with age. 
Psychol. Med. 27 (5), 1205–1213. 
Buyukdura, J.S., McClintock, S.M., Croarkin, P.E., 2011. Psychomotor retardation in 
depression: biological underpinnings, measurement, and treatment. Progress in 
neuro-psychopharmacology & biological psychiatry 35 (2), 395–409. 
Calugi, S., Cassano, G.B., Litta, A., Rucci, P., Benvenuti, A., Miniati, M., Lattanzi, L., 
Mantua, V., Lombardi, V., Fagiolini, A., Frank, E., 2011. Does psychomotor 
retardation define a clinically relevant phenotype of unipolar depression? J. Affect. 
Disord. 129 (1–3), 296–300. 
Coryell, W., Pfohl, B., Zimmerman, M., 1984. The clinical and neuroendocrine features of 
psychotic depression. J. Nerv. Ment. Dis. 172 (9), 521–528. 
Dantchev, N., Widlocher, D.J., 1998. The measurement of retardation in depression. 
J. Clin. Psychiatr. 59 (Suppl. 14), 19–25. 
de Weme, R.J., Hoeksema, T., Goekoop, J.G., 1996. De widlocher remmingsschaal, een 
nederlandse schaal voor het meten van Psychomotorische remming. Acta 
Neuropsychiatr. 8 (3), 56–63. 
First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1999. Structured Clinical 
Interview for DSM-IV axis I Disorders. (Dutch Translation). Swets&Zeitlinger, Lisse, 
the Netherlands.  
Gorwood, P., Richard-Devantoy, S., Bayle, F., Clery-Melin, M.L., 2014. Psychomotor 
retardation is a scar of past depressive episodes, revealed by simple cognitive tests. 
Eur. Neuropsychopharmacol : the journal of the European College of 
Neuropsychopharmacology 24 (10), 1630–1640. 
Guillem, F., Rinaldi, M., Pampoulova, T., Stip, E., 2008. The complex relationships 
between executive functions and positive symptoms in schizophrenia. Psychol. Med. 
38 (6), 853–860. 
Hamilton, M., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 
56–62. 
Heijnen, W., Kamperman, A.M., Tjokrodipo, L.D., Hoogendijk, W.J.G., van den Broek, W. 
W., Birkenhager, T.K., 2019. Influence of age on ECT efficacy in depression and the 
mediating role of psychomotor retardation and psychotic features. J. Psychiatr. Res. 
109, 41–47. 
Hickie, I., Mason, C., Parker, G., Brodaty, H., 1996. Prediction of ECT response: 
validation of a refined sign-based (CORE) system for defining melancholia. Br. J. 
Psychiatry 169 (1), 68–74. 
Janzing, J.G., de Graaf, R., ten Have, M., Vollebergh, W.A., Verhagen, M., Buitelaar, J.K., 
2009. Familiality of depression in the community; associations with gender and 
phenotype of major depressive disorder. Soc. Psychiatr. Psychiatr. Epidemiol. 44 
(12), 1067–1074. 
Lampe, I.K., Kahn, R.S., Heeren, T.J., 2001. Apathy, anhedonia, and psychomotor 
retardation in elderly psychiatric patients and healthy elderly individuals. J. Geriatr. 
Psychiatr. Neurol. 14 (1), 11–16. 
Lattuada, E., Serretti, A., Cusin, C., Gasperini, M., Smeraldi, E., 1999. Symptomatologic 
analysis of psychotic and non-psychotic depression. J. Affect. Disord. 54 (1–2), 
183–187. 
Novick, J.S., Stewart, J.W., Wisniewski, S.R., Cook, I.A., Manev, R., Nierenberg, A.A., 
Rosenbaum, J.F., Shores-Wilson, K., Balasubramani, G.K., Biggs, M.M., Zisook, S., 
Rush, A.J., investigators, S.D., 2005. Clinical and demographic features of atypical 
depression in outpatients with major depressive disorder: preliminary findings from 
STAR*D. J. Clin. Psychiatr. 66 (8), 1002–1011. 
Østergaard, S.D., Meyers, B.S., Flint, A.J., Mulsant, B.H., Whyte, E.M., Ulbricht, C.M., 
Bech, P., Rothschild, A.J., 2014. Measuring treatment response in psychotic 
depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive 
and psychotic symptoms into account. J. Affect. Disord. 160, 68–73. 
Parker, G., 2000. Classifying depression: should paradigms lost be regained? Am. J. 
Psychiatr. 157 (8), 1195–1203. 
Parker, G., Hadzi-Pavlovic, D., Hickie, I., Boyce, P., Mitchell, P., Wilhelm, K., Brodaty, H., 
1991. Distinguishing psychotic and non-psychotic melancholia. J. Affect. Disord. 22 
(3), 135–148. 
Parker, G., McCraw, S., 2017. The properties and utility of the CORE measure of 
melancholia. J. Affect. Disord. 207, 128–135. 
Parker, G., Roussos, J., Mitchell, P., Wilhelm, K., Austin, M.P., Hadzi-Pavlovic, D., 1997. 
Distinguishing psychotic depression from melancholia. J. Affect. Disord. 42 (2–3), 
155–167. 
Schatzberg, A.F., Rothschild, A.J., 1992. Psychotic (delusional) major depression: should 
it be included as a distinct syndrome in DSM-IV? Am. J. Psychiatr. 149 (6), 733–745. 
Schrijvers, D., Hulstijn, W., Sabbe, B.G., 2008. Psychomotor symptoms in depression: a 
diagnostic, pathophysiological and therapeutic tool. J. Affect. Disord. 109 (1–2), 
1–20. 
Smith, M.J., Brebion, G., Banquet, J.P., Allilaire, J.F., 1994. Experimental evidence for 
two dimensions of cognitive disorders in depressives. J. Psychiatr. Res. 28 (4), 
401–411. 
Sobin, C., Sackeim, H.A., 1997. Psychomotor symptoms of depression. Am. J. Psychiatr. 
154 (1), 4–17. 
SPSS IBM Corp, 2017. IBM SPSS Statistics for Windows, Version 25.0 (Armonk, NY).  
Ulbricht, C.M., Dumenci, L., Rothschild, A.J., Lapane, K.L., 2018. Changes in depression 
subtypes among men in STAR*D: a latent transition analysis. Am. J. Men’s Health 12 
(1), 5–13. 
van Diermen, L., Vanmarcke, S., Walther, S., Moens, H., Veltman, E., Fransen, E., 
Sabbe, B., van der Mast, R., Birkenhager, T., Schrijvers, D., 2019. Can psychomotor 
disturbance predict ect outcome in depression? J. Psychiatr. Res. 117, 122–128. 
van Diermen, L., Walther, S., Cools, O., Fransen, E., Birkenhager, T.K., Sabbe, B.C.G., 
Schrijvers, D., 2018. Observer-rated retardation but not agitation corresponds to 
objective motor measures in depression. Acta Neuropsychiatr. 30 (6), 359–364. 
Walther, S., Bernard, J.A., Mittal, V.A., Shankman, S.A., 2019. The utility of an RDoC 
motor domain to understand psychomotor symptoms in depression. Psychol. Med. 
49 (2), 212–216. 
Widlocher, D.J., 1983. Psychomotor retardation: clinical, theoretical, and psychometric 
aspects. Psychiatr. Clin. 6 (1), 27–40. 
Wijkstra, J., Burger, H., van den Broek, W.W., Birkenhager, T.K., Janzing, J.G., Boks, M. 
P., Bruijn, J.A., van der Loos, M.L., Breteler, L.M., Ramaekers, G.M., Verkes, R.J., 
Nolen, W.A., 2010. Treatment of unipolar psychotic depression: a randomized, 
double-blind study comparing imipramine, venlafaxine, and venlafaxine plus 
quetiapine. Acta Psychiatr. Scand. 121 (3), 190–200. 
J.G.E. Janzing et al.                                                                                                                                                                                                                            
